Literature DB >> 25246409

Reliability and clinical correlates of the Astrand-Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder.

Davy Vancampfort1, Hannes Guelinckx2, Marc De Hert2, Brendon Stubbs3, Andrew Soundy4, Simon Rosenbaum5, Els De Schepper2, Michel Probst6.   

Abstract

Cardiovascular fitness is reduced in people with schizophrenia and is related to an increased morbidity and mortality. There is mounting interest in the accurate measurement of cardiovascular fitness in schizophrenia, yet existing measures used in the general population have not been tested on validity and reliability in this high-risk group. Therefore, we examined the reproducibility and feasibility of the Astrand-Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder. Secondary aims were to assess minimal detectable changes, practice effects and the presence of clinical symptoms that are associated with cardio-respiratory fitness (expressed as estimated oxygen uptake). From 47 patients with schizophrenia or schizoaffective disorder two trials of the Astrand-Rhyming test, administered within three days, were analysed. The intraclass correlation coefficient for the estimated oxygen uptake between the two tests was 0.92 (95% confidence interval: 0.85-0.95). The minimal detectable change was 6.5mlO2/min/kg. No practice effect could be detected. A backward regression analysis demonstrated that illness duration, negative symptoms and level of physical activity explained 63.0% of the variance in estimated oxygen uptake. The current study demonstrates that the Astrand-Rhyming test can be recommended for evaluating the aerobic fitness in patients with schizophrenia or schizoaffective disorder.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aerobic fitness; Physical activity; Psychosis

Mesh:

Year:  2014        PMID: 25246409     DOI: 10.1016/j.psychres.2014.08.049

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Reliability and minimal detectable change of a new treadmill-based progressive workload incremental test to measure cardiorespiratory fitness in manual wheelchair users.

Authors:  Cindy Gauthier; Jasmine Arel; Rachel Brosseau; Audrey L Hicks; Dany H Gagnon
Journal:  J Spinal Cord Med       Date:  2017-09-13       Impact factor: 1.985

2.  The effects and determinants of exercise participation in first-episode psychosis: a qualitative study.

Authors:  Joseph Firth; Rebekah Carney; Lauren Jerome; Rebecca Elliott; Paul French; Alison R Yung
Journal:  BMC Psychiatry       Date:  2016-02-20       Impact factor: 3.630

3.  Twelve-week physical exercise does not have a long-lasting effect on kynurenines in plasma of depressed patients.

Authors:  Vincent Millischer; Sophie Erhardt; Örjan Ekblom; Yvonne Forsell; Catharina Lavebratt
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-31       Impact factor: 2.570

4.  An Experimental Study of Step Test Index Combined With Heart Rate Variability in Estimating Maximum Oxygen Uptake in Women With Drug Use Disorder.

Authors:  Kun Wang; Tingran Zhang; Yiyi Ouyang; Haonan Jiang; Meichen Qu; Li Peng; Jiong Luo
Journal:  Front Physiol       Date:  2020-04-30       Impact factor: 4.566

5.  Exercise as an intervention for first-episode psychosis: a feasibility study.

Authors:  Joseph Firth; Rebekah Carney; Rebecca Elliott; Paul French; Sophie Parker; Rebecca McIntyre; Jamie S McPhee; Alison R Yung
Journal:  Early Interv Psychiatry       Date:  2016-03-14       Impact factor: 2.732

6.  The impact of depression and anxiety treatment on biological aging and metabolic stress: study protocol of the MOod treatment with antidepressants or running (MOTAR) study.

Authors:  Bianca A Lever-van Milligen; Josine E Verhoeven; Lianne Schmaal; Laura S van Velzen; Dóra Révész; Catherine N Black; Laura K M Han; Melany Horsfall; Neeltje M Batelaan; Anton J L M van Balkom; Digna J F van Schaik; Patricia van Oppen; Brenda W J H Penninx
Journal:  BMC Psychiatry       Date:  2019-12-30       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.